Antonio
Monge Vega
Investigador hasta 2013
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (7)
1996
-
4-Cyano-2-oxo-1,2,4-oxadiazolo[2,3-a]quinoxaline 5-N-oxides. New synthetic method and reaction with alcohols. Potential cytotoxic activity
Journal of Heterocyclic Chemistry, Vol. 33, Núm. 6, pp. 1671-1677
1995
-
Hypoxia-Selective Agents Derived from 2-Quinoxalinecarbonitrile 1,4-Di-N-oxides. 2
Journal of Medicinal Chemistry, Vol. 38, Núm. 22, pp. 4488-4494
-
Hypoxia-Selective Agents Derived from Quinoxaline 1,4-Di-N-oxides
Journal of Medicinal Chemistry, Vol. 38, Núm. 10, pp. 1786-1792
-
New hypoxia‐selective cytotoxines derived from quinoxaline 1,4‐dioxides
Journal of Heterocyclic Chemistry, Vol. 32, Núm. 4, pp. 1213-1217
1994
-
3‐Amino‐2‐quinoxalinecarbonitrile. New fused quinoxalines with potential cytotoxic activity
Journal of Heterocyclic Chemistry, Vol. 31, Núm. 5, pp. 1135-1139
-
Hypoxia-selective antitumor agents derived from 1,9-diazaanthracene
European Journal of Medicinal Chemistry, Vol. 29, Núm. 6, pp. 441-445
-
Synthesis and preliminary cytotoxic activity of dimethoxy‐acridines and dimethoxynitroacridines
Journal of Heterocyclic Chemistry, Vol. 31, Núm. 6, pp. 1455-1460